How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?

The billion dollar question. For patients with resectable stage II-IIIA NSCLC, how do you choose between neoadjuvant and adjuvant chemo-immunotherapy in light of the recent FDA approval of the CheckMate-816 regimen? Of course, this approval quickly followed in the footsteps of the FDA approval of at...

Important to keep in mind that we've had no head-to-head comparison of neoadjuvant versus adjuvant immunotherapy, nor has there been an appetite to address this important question thus far. In parsing the existing data, it is important that we remember what we don't know, to avoid extinguishing inte...

In potentially resectable non-small cell lung cancer (NSCLC) patients, phase 3 randomized studies in the adjuvant setting (IMpower010 and KEYNOTE-091), neoadjuvant setting (CheckMate 816) and perioperative setting (KEYNOTE-671, AEGEAN, and CheckMate 77T) have shown statistically significant and clin...